Iodine makes the stock market news

This was on the yahoo Iodine list today. Symbollon is Jack Kessler's company that hopes to market a prescription Iodine drug.
Essentially I believe we're all getting the same thing with our cheap iodine. However still if his company takes off, perhaps Iodine will finally get some of the research money it deserves and we'll see some big changes happen in medical care.
Lily


Featured today on HotChicksStockPicks.com - Symbollon for IoGen

If it takes the stock market to get the world's attention, then so
be it.

Spotlight Stock: Symbollon Pharmaceuticals, Inc.
Symbollon Pharmaceuticals, Inc.
The First Company to Develop Non-Hormonal Treatment for Breast
Cancer,
Female Reproductive Organ Diseases Now In FDA Phase III Pivotal
Trials
Evaluating the Clinical Effects of IoGenTM on Fibrocystic Breast
Disease:

Iodine has been used as an antimicrobial for the last century. Much
has been written about molecular iodine yet many women suffering
from Fibrocystic Breast Disease (FBD) are unaware that studies being
conducted may soon yield an effective nonhormonal treatment. While
there are several Breast Cancer drugs on the market, all available
hormonal therapies have significant adverse events. In contrast,
IoGen (I2) is a nonhormonal treatment that allows for safe long-term
use with little or no side effects.
"Current research provides substantive support for the initiation of
human clinical studies on the use of molecular iodine as a treatment
for breast disease," stated Paul Desjourdy, President and CEO,
Symbollon Pharmaceuticals, Inc. "The possibility that IoGen may be
used as a treatment for Breast Cancer makes it all the more
important that we expedite the commercialization time line."
The Company believes IoGen has the ability to eliminate excess cell
growth in female reproduc­tive tissue, including the breast, ovaries
and uterus. Other indications for IoGen include the treatment or
prevention of endometriosis, ovarian cysts, and premenopausal breast
cancer.
Symbollon Pharmaceuticals, Inc. has success­fully completed 6/8
clinical trials required for FDA approval. The company is now in the
7th -­the first of two FDA Phase III clinical trials for the
evaluation of IoGen for pain/tenderness associ­ated with FBD and with
potential to treat female reproductive organ cancers.
Healing with I2 Technology
The importance of I2 in the treatments for mammary gland
dysfunctions has been corrobo­rated in human and animal models.
Seaweeds, containing high quantities of iodine, in several chemical
forms including I2, have been associated with low incidences of
benign and malignant breast disease in Asian women. Past studies by
independent researchers have supported the possible effectiveness of
molecular iodine I2 as a treatment for breast cancer.
Researchers at Drexel University College of Medicine found that
molecular iodine alters the gene expression profile in the human
breastcancer cells. Dr. Bernard Eskin remarked that these changes
may be responsible for molecular iodine's inhibition of breast
cancer promotion that has been repeatedly observed in animal models.
Some researchers investigating the connec­tion between breast tissue
and iodine observed that frequent childbirth and a long lactation
period are known to reduce the risk of breast cancer.
Symbollon is now conducting its IoGen Phase III pivotal pain study.
Results are expected in first quarter of 2008. For more information
on IoGen(TM), please visit the company's web site at:

http://www.symbollon.com
or
http://www.mybreastpain.com.



http://www.hotchicksstockpicks.com/index.php?

option=com_content&task=blogsection&id=10&Itemid=28

---------------------------